Oncology Business Management | Specialty

Choosing Second-Line Therapy for Squamous NSCLC

February 21st 2017

Maintenance Therapy for Squamous NSCLC

February 21st 2017

Chemotherapy for Newly Diagnosed Squamous NSCLC

February 21st 2017

Promising Immunotherapy Trials in Squamous NSCLC

February 21st 2017

Pseudoprogression on Immunotherapy in Squamous NSCLC

February 21st 2017

Toxicities Associated with Anti-PD-1 Immunotherapy

February 21st 2017

Pembrolizumab in Newly Diagnosed Squamous NSCLC

February 21st 2017

PD-L1 Testing in Squamous NSCLC

February 21st 2017

EGFR & ALK/ROS1 Testing in Squamous NSCLC

February 21st 2017

Big Data Strives for Individualized Coverage

February 21st 2017

Healthcare spending is one of the largest expenses for a company and, more and more, employers are using population-based Big Data to ensure their employees have coverage tailored to their needs at a reasonable cost.

Immunotherapy Requires New Strategies for Oncology Practices

February 21st 2017

Immuno-oncology drugs can improve the level of care in many respects, but they bring a host of problems related to implementation that demands a new set of strategies.

Bundles Offer Better Outcomes and Savings

February 15th 2017

The primary goal of a cancer diagnosis is to end up with the best possible outcome, and there are always several highways of care, or bundles, to choose from.

ACA May Be a Tough Act to Follow

February 10th 2017

The Republican push to repeal the Affordable Care Act has sent anxiety levels soaring among oncologists and their patients, due largely to the great uncertainty about how exactly Congress will proceed.

The New Administration May Speed Up the Pace of Innovation

February 5th 2017

With ambitious goals to improve outcomes and lower the cost of care, CMS has placed a lot of faith in its Oncology Care Model, an alternative payment model.

FDA Grants Pembrolizumab Priority Review in Second-Line Bladder Cancer

February 4th 2017

The FDA has granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who progress following platinum-containing chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor.

Dr. Sanft on Sequencing of Treatments for HER2+ Breast Cancer

February 3rd 2017

Tara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.

Practicing Oncology in the Gray Zone

February 1st 2017

"Uncertainty" is a routine dilemma when discussing a prognosis with a patient with cancer and his or her family. The prognosis is, at best, a statistical probability—assuming the available objective data are somewhat representative of the individual patient.

Who Is at the Controls of 340B?

January 29th 2017

The 340B Drug Pricing Program, designed to provide support for out-patient drug purchases, severely lacks federal oversight, said BRG Healthcare, the business advisory group, in a report sponsored by the Alliance for Integrity and Reform of 340B (AIR340B).

CMS Keeps Innovation Under Lock and Key

January 27th 2017

Several organizations are developing alternative payment models they hope CMS will adopt as ways to encourage oncologists to deliver care at a lower cost while improving its quality. If approved, these proposals could become customized alternatives to the agency’s Oncology Care Model.

Protect Yourself From Malpractice Claims

January 25th 2017

Compared with other specialists, medical oncologists are not often the target of malpractice litigation. Even so, they still get sued.